4.4 Review

Familial Hypercholesterolemia: An Under-recognized but Significant Concern in Cardiology Practice

期刊

CLINICAL CARDIOLOGY
卷 37, 期 2, 页码 119-125

出版社

WILEY-BLACKWELL
DOI: 10.1002/clc.22223

关键词

-

资金

  1. Genzyme, a Sanofi company (Cambridge, MA)
  2. Genzyme

向作者/读者索取更多资源

Familial hypercholesterolemia (FH) is a common disorder in which genetic mutations in at least 1 of several genes lead to significantly increased levels of lipoproteins, in particular, low-density lipoprotein cholesterol. Most commonly, mutations in the low-density lipoprotein receptor gene result in high plasma levels of apolipoprotein B-containing lipoproteins (eg, low-density lipoprotein and lipoprotein(a)). High plasma levels of lipoproteins increase the risk of cardiovascular events by as much as 20-fold if left untreated. A 2011 survey of cardiologists performed by the American College of Cardiology (ACC) suggests that there is a need for greater awareness of FH among cardiologists with regard to its prevalence and heritability, and of the risk of cardiovascular (CV) disease associated with the disorder, such as premature coronary heart disease. Given that many patients with FH may first present to CV specialists at the time of a major coronary event, it is critical that cardiologists have strategies to manage this high-risk subset of patients. This brief review responds to areas of need identified in the ACC survey and is intended to provide current information about FH and increase awareness about this disorder among cardiologists.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
Article Cardiac & Cardiovascular Systems

Comparison of machine-learning models for the prediction of 1-year adverse outcomes of patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction

Saeed Tofighi, Hamidreza Poorhosseini, Yaser Jenab, Mohammad Alidoosti, Mohammad Sadeghian, Mehdi Mehrani, Zhale Tabrizi, Parisa Hashemi

Summary: This study aimed to predict adverse clinical outcomes in STEMI patients treated with primary PCI using machine learning models. The results showed that the DRF and GBM models had the best performance in predicting major adverse cardiovascular events.

CLINICAL CARDIOLOGY (2024)